Alt-Support-Diabetes.org The Official Website for the Newsgroup

  • Skip to content
  • Jump to main navigation and login

Nav view search

Navigation

Search

Welcome to Alt-Support-Diabetes.org

Alt-Support-Diabetes.org is under new management.

The previous webmaster was discouraged by the lack of interest in the site, and the death of Usenet in general. The active members in the alt.support.diabetes newsgroup weren't even referring to it anymore.

The domain registration for Alt-Support-Diabetes.org was paid years in advance by Mack, who was a frequent poster on the alt.support.diabetes newsgroup and an Alt-Support-Diabetes.org Webmaster. So it doesn't make sense to have a "We're shutdown" message for the next several years. However, it's probable the site will disappear on 12 April 2024.

Some of the information here is very old as the original site was established in 2001 and much of it has never been updated. But it's still a valuable resource. So it's back.

If you would like to contribute content for the site, please contact the ASD Webmaster. Articles attributed to ASD Webmaster as contributor are those for which the true author cannot be determined. If you know who should be credited, please let us know.


Alt-Support-Diabetes (ASD) is an online support group of diabetics, their families and friends. We use this forum to freely share our personal experiences, knowledge, hopes, successes and frustrations concerning diabetes and it's impact on our lives. Currently we are using three major forums: the newsgroup alt.support.diabetes, our IRC chat room, and this website.

Newsgroups are one of the oldest parts of the internet called UseNet. It even pre-dates the World Wide Web. Currently there are over 70,000 individual newsgroups.

We encourage everyone to first read the Newsgroups FAQ. It explains the few do's and don'ts and some basic information about posting to a UseNet forum such as ours.

Disclaimer

The information made available through this web site is not intended to replace the services of a physician. It is provided for informational purposes only and is not a substitute for professional medical advice.

Diabetes News from MIT

20 January 2021

MIT news feed about: Diabetes
  • On planetary change and human health
    MIT anthropologist Amy Moran-Thomas reflects on the deep connection between planetary and human well-being.
  • “Living drug factories” might treat diabetes and other diseases
    Chemical engineers have developed a way to protect transplanted drug-producing cells from immune system rejection.
  • Mathematical model could lead to better treatment for diabetes
    A new model can predict which types of glucose-responsive insulin will work in humans and animals.
  • Health care innovators strive to make a difference
    A week of learning with MIT Bootcamps sparked ideas that Jal Panchal and Maria Hahn are taking forward to solve problems in health care.
  • Hydration sensor could improve dialysis
    Noninvasive device could benefit patients with kidney disease, congestive heart failure, or dehydration.

Diabetes News from ScienceDaily

19 January 2021

Learn about early diabetes symptoms, diabetic diet information, diabetes care, type 1 diabetes, insulin resistance and type 2 diabetes. Read the latest medical research on diabetes.
  • Could altering mealtimes prevent development of Type 2 diabetes?
    An innovative new study is set to examine if changing our mealtimes to earlier or later in the day could reduce the risk of developing Type 2 diabetes.
  • ADA lowers target HbA1C levels for children with type-1 diabetes
    In early 2020, upon recommendation by leading endocrinologists, American Diabetes Association lowered the target hemoglobin A1C guidelines for children with type 1 diabetes. Their goal in recommending stricter glucose control was to ensure children with type 1 diabetes have better immediate and long-term health outcomes with fewer health complications and reduced mortality rates. Researchers now discuss the evidence and rationale behind this new recommendation.
  • Metformin use reduces risk of death for patients with COVID-19 and diabetes, study finds
    Use of the diabetes drug metformin -- before a diagnosis of COVID-19 -- is associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes, according to a new study. Diabetes is a significant comorbidity for COVID-19. This beneficial effect remained, even after correcting for age, sex, race, obesity, and hypertension or chronic kidney disease and heart failure.
  • Short term low carbohydrate diet linked to remission of type 2 diabetes
    Patients with type 2 diabetes who follow a strict low carbohydrate diet for six months may experience greater rates of remission compared with other recommended diets without adverse effects, a new study suggests.
  • High doses of saccharin don't lead to diabetes in healthy adults, study finds
    A new study has found that the sugar substitute saccharin doesn't lead to the development of diabetes in healthy adults.

Main Menu

  • Home
  • About ASD
  • FAQs
  • Newly Diagnosed
  • Newsgroup Posters
  • Resources

Popular Stuff

  • Hyperlipid by Petro Dobromylskyj
  • The 5% Club
  • A Short History of the Alt.Support.Diabetes Newsgroup
  • Newsgroups FAQ
  • Photo Gallery
  • Beef Stroganoff
  • Blogs, Books and Websites
  • Pumpkin Sausage Soup
  • Grady, Quentin John Freeth

Updated Stuff

  • Low-Carb Chili
  • Egg Scramble
  • Carb Classification of Fruits and Vegetables
  • The 5% Club
  • No-Bake Jello Cheesecake
  • Beef Stroganoff
  • Pumpkin Sausage Soup
  • Latest alt.support.diabetes Topics (Google Groups)
  • Diabetes News from MedlinePlus

Information contained within this site is for educational purposes only. None of the participants are doctors.
We share only what we have learned by being diabetic ourselves. Please consult your doctor -- ALWAYS!
This domain expires on 12 April 2024. Contributors retain all copyright to the material submitted. For questions, comments and suggestions contact the ASD Webmaster.